New study offers reassurance for patients with some cancer-linked genes
Peer-Reviewed Publication
Updates every hour. Last Updated: 1-May-2025 11:08 ET (1-May-2025 15:08 GMT/UTC)
As more people receive genetic testing after a cancer diagnosis, newer variants have been identified that increase risk of developing cancer. A new study led by the University of Michigan Rogel Cancer Center finds that patients with three of these variants face no extra risk of dying from their cancer.
The New York Genome Center announces Bing Ren, PhD, as the New Scientific Director and CEO of the New York Genome Center and Professor in the Departments of Genetics and Development, Biochemistry and Molecular Biophysics, and Systems Biology at Columbia University.
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be discontinued. This transcript that is unique for CML is more sensitive and accurate than the current standard, real-time quantitative PCR (RT-qPCR), for detecting ultralow levels of residual leukemic disease. Results are reported in a novel study in The Journal of Molecular Diagnostics, published by Elsevier.
In a new study, researchers from Karolinska Institutet have shown that so-called interval cancers, which are detected between two screening sessions, account for a significant proportion of breast cancer cases and that certain risk factors may increase the likelihood of developing this type of cancer. The study was published in the journal JAMA Oncology.
A new study published in Engineering has identified enolase 2 (ENO2) as a key factor in the lymphatic metastasis of head and neck squamous cell carcinoma (HNSCC). The research reveals how ENO2 and its metabolite phosphoenolpyruvate (PEP) promote cancer cell invasion and macrophage polarization, and shows that inhibiting ENO2 can potentially slow down HNSCC metastasis.
Researchers have discovered a groundbreaking use of terahertz (THz) imaging to visualize cochlear structures in mice, offering non-invasive, high-resolution diagnostics. By creating 3D reconstructions, this technology opens new possibilities for diagnosing hearing loss and other conditions. THz imaging could lead to miniaturized devices, like THz endoscopes and otoscopes, revolutionizing diagnostics for hearing loss, cancer, and more. With the potential to enhance diagnostic speed, accuracy, and patient outcomes, THz imaging could transform medical practices.